Findings

What do systematic reviews say?

2 questions · 2 findings · 1 reviews

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 1 · 50%Low 0 · 0%Moderate 0 · 0%High 1 · 50%

All‐cause mortality · people at high risk of CVD (history of CVD or high LDL‐C despite treatment)

It is very uncertain whether evolocumab changes all‐cause mortality compared with ezetimibe and statins (very low certainty).

1 finding from 1 review

PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease 2020 · Cochrane Headline outcomes only
OR 0.43 [0.14, 1.3]
3 studies · 5223 participants
Very low

All‐cause mortality · people at high risk of CVD (history of CVD or high LDL‐C despite treatment)

Evolocumab showed no clear difference in all‐cause mortality compared with placebo (high certainty).

1 finding from 1 review

PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease 2020 · Cochrane Headline outcomes only
OR 1.04 [0.91, 1.19]
3 studies · 29432 participants
High